期刊文献+

塞来昔布联合HMG-CoA还原酶抑制剂对人肝癌裸鼠皮下移植瘤生长的影响

COMBINED INHIBITORY EFFECTS OF CELECOXIB AND HMG-COA REDUCTASE INHIBITOR ON THE GROWTH OF HUMAN HEPATOCELLAR CARCINOMA CELLS IN A XENOGRAFT MODEL
下载PDF
导出
摘要 目的探讨选择性环氧化酶-2(Cyclooxygenase-2,COX-2)抑制剂塞来昔布(celecoxib)联合HMG-CoA还原酶抑制剂氟伐他汀(fluvastatin)对实验性人肝癌裸鼠皮下移植瘤生长的影响。方法接种BEL-7402肝癌细胞株的裸鼠,分别予以塞来昔布,氟伐他汀及联合用药,并对肿瘤生长进行评估。ki67免疫组化染色检测肿瘤细胞增殖,TUNEL法检测凋亡,免疫蛋白印迹法(Western blot)检测Akt、磷酸化Akt(p-Akt)蛋白的表达。结果联合应用塞来昔布及氟伐他汀明显抑制肿瘤生长,其机制可能与抑制肿瘤细胞增殖、诱导凋亡以及抑制Akt磷酸化有关。结论本研究表明塞来昔布及氟伐他汀联合用药可能更有效地治疗肝癌,为进一步防治肝癌提供了新的方法。 Objective To evaluate the effects of celecoxib(a selective COX-2 inhibitor)alone and in combination with fluvastatin(a HMG-CoA reductase inhibitor)on the growth of hepatocellular carcinoma xenograft in athymic nude mice.Methods Nude mice implanted with hepatocellular carcinoma BEL-7402 cells were given celecoxib and fluvastatin,alone and in combination,and their effect on tumor growth was evaluated.Tumor cell proliferation was analyzed by Ki-67 immunostaining and Apoptosis by TUNEL assay.Levels of phosphorylated(p-Akt)and total Akt was determined by Western blot analysis.Results In vivo,combination treatment with celecoxib and fluvastatin resulted in enhanced tumor growth inhibition,inhibition of tumor cell proliferation and apoptosis induction compared with results of single-agent treatment.Our results further demonstrated that the combinational effects of celecoxib/fluvastatin were associated with decreased levels of phospho-Akt.Conclusion These results suggest that the combination of celecoxib and fluvastatin would be more efficacious for the treatment of HCC than either treatment alone.The present study may be important in future exploration of the potential application of the combined approach in the treatment of Hepatocellular carcinoma.
出处 《肝胆外科杂志》 2010年第2期139-142,共4页 Journal of Hepatobiliary Surgery
基金 安徽省2007年度重点科研计划项目(07020304100)
关键词 原发性肝癌 环氧化酶-2 塞来昔布 氟伐他汀 裸鼠 hepatocellular carcinoma ( HCC ) cyclooxygenase-2 celecoxib fluvastatin nude mice
  • 相关文献

参考文献29

  • 1TM Block, AS Mehta, CJ Fimmel, et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene,2003 ,22 :5093 - 5107.
  • 2汤钊猷.试论原发性肝癌复发转移的研究[J].中华实验外科杂志,1999,16(6):485-486. 被引量:20
  • 3Kulp SK, Yang YT, Hung CC, et al 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyelooxygenase-2- Independent Target for Celecoxib in Prostate Cancer Cells. Cancer res,2004,64:1444 - 1451.
  • 4El-Rayes BF, Ali S, Sarkar FH, et al. Cyclooxygenase-2-dependent and-independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther,2004,3 : 1421 - 1426.
  • 5Qin J,Yuan J,Li L,et al. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomed & Pharmacother,2009 ,63 :241 -48.
  • 6Xie H,Gao L,Chai N,et al. Chai Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Mol Carcinog, 2009,48:56 -65.
  • 7Horiguchi A, Sumitomo M, Asakuma J, et al. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis. Clin Cancer Res, 2004, 15:8648 - 55.
  • 8Cafforio P, Darmnacco F, Gernone A, et al. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis,2005,26:883 - 891.
  • 9Wang CY, Liu PY, Liao JK, et al. Pleiotropic effects of statin therapy : molecular mechanisms and clinical results. Trends Mol Med, 2008, 14:37 -44.
  • 10Hindler K,Cleeland CS,Rivera E,et al. The role of statins in cancer therapy. Oncologist ,2006,11:306 - 315.

二级参考文献11

  • 1陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤,2005,14(1):28-31. 被引量:93
  • 2Dong-ShengHuang Ke-ZhenShen Jian-FengWei Thng-BoLiang Shu-SenZheng Hai-YangXie.Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2[J].World Journal of Gastroenterology,2005,11(2):204-207. 被引量:31
  • 3PARKRN DM,BRAY F,FERLAY J,et al.Estimating the world cancer burden:Globocan 2000[J].Int J Cancer,2001,94:153-156.
  • 4DI BISCEGLIE AM.Epidemiology and clinical presentation of hepatocellular carcinoma[J].J Vasc Interv Radiol,2002,13:S169-171.
  • 5BRUIX J,LLOVENT JM.Prognostic prediction and treatment strategy in hepatocellular carcinoma[J].Hepatology,2002,35:519-524.
  • 6BAE S H,JUNG E S,PARK Y M,et al.Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor,NS-398[J].Clin Cancer Res,2001,7(5):1410-1418.
  • 7KOGA H,SAKISAKA S,OHISHI M,et al.Expression of cyclooxygenase-2 in human hepatocellular carcinoma:relevance to tumor dedifferentiation[J].Hepatology,1999,29(3):688-696.
  • 8SUNG YK,HWANG SY,KIM JO,et al.The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis[J].Mol Cells,2004,17(1):35-38.
  • 9KONDON M,YAMAMOTO H,NAGANO H,et al.Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma[J].Clin Cancer Res,1999,5 (12):4005-4012.
  • 10KIRKIN V,JOOS S,ZORNIG M.The role of bcl-2 family members in tumorigenesis[J].Biochim Biophys Acta,2004,1644(2-3):229-249.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部